IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients

Journal of Gastroenterology

Volumn 47, Issue 7, 2012, Pages 834-844

  Ohnishi, Mayu ^a,b   Tsuge, Masataka ^a,b   Kohno, Tomohiko ^a,b   Zhang, Yizhou ^a,b   Abe, Hiromi ^a,b   Hyogo, Hideyuki ^a,b   Kimura, Yuki ^a,b   Miki, Daiki ^a,b,c   Hiraga, Nobuhiko ^a,b   Imamura, Michio ^a,b   Takahashi, Shoichi ^a,b   Ochi, Hidenori ^a,b,c   Hayes, C Nelson ^a,b   Tanaka, Shinji ^a   Arihiro, Koji ^d   Chayama, Kazuaki ^a,b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c RIKEN   (Japan)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Core substitution; Fatty change; HCV; IL28B; SNP

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GUANOSINE TRIPHOSPHATE; INTERLEUKIN 28B; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; COMPUTER PROGRAM; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; YOUNG ADULT;

EID: 84865010501     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0550-y     Document Type: Article

References (45)

1. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494-500.
2. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999;10:439-49.
3. Lee SH, Kim YK, Kim CS, et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol. 2005;175:8226-35.
4. Akuta N, Chayama K, Suzuki F, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 Allele. J Med Virol. 2001;64:109-16.
5. Dusheiko GM. The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepat. 1998;5(Suppl 1):9-12.
6. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930-8.
7. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228-33.
8. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-95.
9. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-6.
10. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C.Arandomized, doubleblind, placebo-controlled trial. N Engl J Med. 1989;321:1506-10.
11. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-9.
12. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-92.
13. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-7.
14. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 1997;26:961-6.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
16. Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology. 2003;38:66-74.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
18. Akuta N, Suzuki F, Hirakawa M, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81:452-8.
19. Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686-95.
20. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and lowdensity lipoprotein cholesterol levels. J Hepatol. 2007;46:403-10.
21. Akuta N, Suzuki F, Kawamura Y, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007;50:361-8.
22. Kitamura S, Tsuge M, Hatakeyama T, et al. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir Ther. 2010;15:1087-97.
23. Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952-63.
24. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
25. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-45, 1345.e1-7.
26. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-4.
27. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-9.
28. Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439-43.
29. Haraguchi A, Ogai Y, Senoo E, et al. Verification of the addiction severity index Japanese version (ASI-J) as a treatment-customization, prediction, and comparison tool for alcohol-dependent individuals. Int J Environ Res Public Health. 2009;6:2205-25.
30. Osaki Y, Tanihata T, Ohida T, et al. Decrease in the prevalence of adolescent alcohol use and its possible causes in Japan: periodical nationwide cross-sectional surveys. Alcohol Clin Exp Res. 2009;33:247-54.
31. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20.
32. Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83-90.
33. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferonribavirin combination therapy. Intervirology. 2005;48:372-80.
34. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 1990;87:9524-8.
35. Ochi H, Maekawa T, Abe H, et al. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J Gen Virol. 2011;92:1071-81.
36. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572-7.
37. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol. 2005;43:38-44.
38. Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virusassociated steatosis. J Hepatol. 2011;55:529-35.
39. Trepo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C[G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54:60-9.
40. Valenti L, Alisi A, Nobili V. I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. Hepatology. 2011.
41. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-97.
42. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78(Pt 7):1527-31.
43. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006;55: 123-30.
44. Kurosaki M, Matsunaga K, Hirayama I, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res. 2010;40:251-60.
45. Tillmann HL, Patel K, Muir AJ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011;55:1195-200.